These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Author: Reed AB, Parekh DJ.
    Journal: Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950.
    Abstract:
    PURPOSE OF REVIEW: We examine the role of 5-alpha reductase inhibitors in prevention and diagnosis of prostate cancer, highlight the basic science supporting this role, and analyze the phase III clinical trials addressing the association between 5-alpha reductase inhibitor use and prostate cancer. RECENT FINDINGS: To date, the Prostate Cancer Prevention trial (PCPT) is the only reported phase III randomized clinical trial to evaluate the role of 5-alpha reductase inhibitors in the prevention and treatment of prostate cancer. The original PCPT data revealed that finasteride reduced the risk of prostate cancer by approximately 25% in comparison with placebo. However, patients who received finasteride had a greater incidence of high-grade tumors, which prohibited acceptance of finasteride as a chemopreventive agent by most urologists. Recent updates of the PCPT findings confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to its effects on improving the performance characteristics of prostate-specific antigen and prostate biopsy. There was no increase in high-grade prostate cancer. Rather, there was improved detection of high-grade prostate cancer due to decreased prostate volume. SUMMARY: Finasteride is a valuable chemopreventive tool because it reduces the risk of prostate cancer, including high-grade cancer, and enhances our ability to detect high-grade disease.
    [Abstract] [Full Text] [Related] [New Search]